top of page
Recruiting: Open

Respiratory Syncytial Virus (RSV) / Human Metapneumovirus (hMPV) vaccine trial

Clinical Trial

Description

  • Randomised double-blinded study

  • 4 treatment groups

    • RSV/hMPV mRNA vaccine (dosage type 1)

    • RSV/hMPV mRNA vaccine (dosage type 2)

    • RSV mRNA vaccine

    • hMPV mRNA vaccine

Trial length

6 months

Participant age

Participant ages can range from 18 to 49, and 60+

Patient eligibility

  • Female participants must NOT be pregnant 

  • Female participants must NOT be breastfeeding

  • No history of immunosuppressive or immunodeficient conditions

  • Healthy participants within the eligible age range (18-49 or 60+)

6 onsite visits are required from patients.

Follow-up inclusions

Objectives

To assess the immunogenicity of different formulations of the RSV/hMPV, monovalent RSV, and monovalent hMPV vaccine candidates.

Interested in participating?

Send us a message or give us a call here

Got questions?

Read our common queries about clinical trials, participation processes, safety measures, and more.

Get in touch with us

Our friendly team would love to hear from you! 

bottom of page